How Symbicort Relieves Asthma Symptoms
Symbicort combines budesonide, an inhaled corticosteroid (ICS), and formoterol, a long-acting beta2-agonist (LABA). It treats asthma by reducing airway inflammation and relaxing bronchial muscles, improving breathing in patients with moderate to severe persistent asthma.[1]
Budesonide decreases inflammation by inhibiting inflammatory cells and mediators like cytokines, which swell and narrow airways during asthma attacks. Formoterol stimulates beta2 receptors in airway smooth muscle, causing relaxation and bronchodilation that lasts 12 hours, preventing bronchospasm.[1][2]
Patients inhale it twice daily as maintenance therapy; formoterol also acts quickly (within 1-3 minutes) for symptom relief, making it a controller and reliever in one device.[1]
How It Differs from Short-Acting Inhalers
Unlike short-acting beta-agonists (SABAs) like albuterol, which provide quick relief for 4-6 hours but don't address inflammation, Symbicort targets both acute and chronic aspects. It's not for sudden attacks—use a rescue inhaler instead.[1][2]
Compared to ICS-only inhalers (e.g., Pulmicort), adding formoterol enhances lung function faster and reduces exacerbations by 25-30% in trials.[3]
Common Doses and Usage for Asthma
Adults and adolescents (12+): 80/4.5 mcg or 160/4.5 mcg (budesonide/formoterol) per inhalation, 2 inhalations twice daily. Children (6-11): 80/4.5 mcg, 2 inhalations twice daily. Rinse mouth after use to prevent thrush.[1]
Risks and Side Effects Patients Report
Most common: oral candidiasis, headache, throat irritation. LABAs carry a black box warning for asthma-related death risk when used alone; Symbicort mitigates this via ICS combination. Monitor for pneumonia in COPD overlap cases, though less common in asthma. Long-term ICS use may slow growth in kids—benefits typically outweigh risks.[1][2]
Avoid in acute severe asthma or without ICS history.[1]
Who Makes Symbicort and When Does Patent Protection End?
AstraZeneca manufactures Symbicort (turbuhaler or pressurized MDI). U.S. patents expired around 2015-2022 for some formulations, enabling generics like Breyna (2020 approval). Full exclusivity ended; check DrugPatentWatch.com for latest generic entry dates by strength.[4]
[1] Symbicort Prescribing Information, AstraZeneca. https://www.symbicort.com/asthma.html
[2] Global Initiative for Asthma (GINA) Report 2023. https://ginasthma.org/
[3] New England Journal of Medicine, Symbicort Studies (e.g., SYGMA trials), 2018-2019.
[4] DrugPatentWatch.com, Symbicort Patents. https://www.drugpatentwatch.com/p/tradename/SYMBICORT